{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-000437","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.582553+00:00","generated_at":"2026-05-16T11:32:19.894407+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Genprex reports positive preclinical GPX-002 data in T2D; first NHP achieved normal glucose tolerance at 7 months","bullets":["First T2D NHP received intraductal AAV infusion of GPX-002 (Pdx1+MafA) and showed normal glucose tolerance test at 7 months.","Second NHP via direct pancreas injection improved glucose tolerance at 3 months but did not reach normal levels.","T2D mice treated with GPX-002 showed reversal of hyperglycemia and normal glucose levels at 4 weeks post-surgery.","GPX-002 aims to rejuvenate exhausted beta cells; company says data supports potential to address 90-95% of diabetes patients (T2D).","Preclinical studies continuing; formal toxicology and IND submission planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-000437","json":"https://secwatch.observer/filing/0001437749-26-000437.json","markdown":"https://secwatch.observer/filing/0001437749-26-000437.md","text":"https://secwatch.observer/filing/0001437749-26-000437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926000437/0001437749-26-000437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926000437/gnpx20251201_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:32:19.894407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}